首页> 外文期刊>Hepato-gastroenterology. >Preoperative peripheral blood human telomerase reverse transcriptase mRNA concentration is not a prognostic factor for resection of hepatocellular carcinoma
【24h】

Preoperative peripheral blood human telomerase reverse transcriptase mRNA concentration is not a prognostic factor for resection of hepatocellular carcinoma

机译:术前外周血人端粒酶逆转录酶mRNA浓度不是肝细胞癌切除的预后因素

获取原文
获取原文并翻译 | 示例
           

摘要

Background/Aims: Hepatocellular carcinoma (HCC) often recurs after complete surgical resection. Detection of markers of residual circulating cancer cells may predict postoperative HCC recurrence. Human telomerase reverse transcriptase (hTERT) mRNA may be a candidate tumor marker. Methodology: We prospectively assessed the expression patterns and prognostic value of preoperative peripheral blood hTERT mRNA in patients with HCC undergoing hepatic resection (n=17) or liver transplantation (n=6). As controls, we assessed hTERT mRNA in patients with liver cirrhosis without HCC (n=6) and in living liver donors (n=4). Concentrations of hTERT mRNA were measured by real-time quantitative reverse transcription polymerase chain reaction (RT-PCR). Results: No significant difference was observed in the levels of hTERT mRNA between the HCC and control groups. Only alpha-fetoprotein ≥400ng/mL was associated with greater expression levels of hTERT mRNA. At a median follow-up of 30 months, HCC recurred in 10 of 17 resected patients, but in none of the 6 liver transplant recipients. hTERT mRNA concentration was not associated with HCC recurrence after either resection or liver transplantation. Conclusions: Peripheral blood hTERT mRNA concentration is not a likely marker for the diagnosis or prognosis of HCC, especially in patients undergoing resection. Owing to the small number of transplanted patients assessed, the clinical significance of hTERT mRNA concentration was not objectively verified, suggesting the need for a study in larger numbers of HCC patients undergoing liver transplantation.
机译:背景/目的:肝癌(HCC)常在完全手术切除后复发。检测残留循环癌细胞的标志物可预测术后HCC复发。人端粒酶逆转录酶(hTERT)mRNA可能是候选肿瘤标志物。方法:我们前瞻性评估了接受肝切除(n = 17)或肝移植(n = 6)的肝癌患者术前外周血hTERT mRNA的表达模式和预后价值。作为对照,我们评估了无HCC肝硬化患者(n = 6)和活体肝供体(n = 4)中的hTERT mRNA。通过实时定量逆转录聚合酶链反应(RT-PCR)测量hTERT mRNA的浓度。结果:HCC组和对照组之间的hTERT mRNA水平没有显着差异。只有甲胎蛋白≥400ng/ mL与hTERT mRNA的更高表达水平相关。在30个月的中位随访中,在17例切除的患者中有10例复发了HCC,但在6例肝移植患者中均未复发。切除或肝移植后,hTERT mRNA浓度与HCC复发无关。结论:外周血hTERT mRNA的浓度不是诊断或预后肝癌的可能标志,尤其是在接受切除的患者中。由于评估的移植患者人数很少,因此尚未客观验证hTERT mRNA浓度的临床意义,这表明需要对大量接受肝移植的HCC患者进行研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号